|1.||Amidon, Gordon L: 2 articles (11/2007 - 07/2007)|
|2.||Mittal, Sachin: 2 articles (11/2007 - 07/2007)|
|3.||Lee, Kyung-Dall: 1 article (11/2007)|
|4.||Tsume, Yasuhiro: 1 article (11/2007)|
|5.||Hilfinger, John M: 1 article (11/2007)|
|6.||Landowski, Christopher P: 1 article (11/2007)|
|7.||Vig, Balvinder S: 1 article (07/2007)|
|8.||Song, Xueqin: 1 article (07/2007)|
|1.||Melanoma (Melanoma, Malignant)
11/01/2007 - "Prophalan-L thus demonstrates higher therapeutic index than melphalan in the murine melanoma model."
07/01/2007 - "Hence, prophalan-L: , a stable prodrug of melphalan, exhibits potential for efficiently targeting melanoma with reduced systemic toxicity."
11/01/2007 - "Prophalan-L exhibited 2- to 2.5-fold higher hydrolytic and cytotoxic activity than prophalan-D, the D-analog, in B16-F10 murine melanoma cells in vitro. "
11/01/2007 - "Proline prodrug of melphalan, prophalan-L, demonstrates high therapeutic index in a murine melanoma model."
11/01/2007 - "The therapeutic efficacy of prophalan-L, the L-proline prodrug of melphalan that demonstrated prolidase-dependent bioactivation to melphalan, was examined in vivo in a mouse melanoma model. "
11/01/2007 - "Tumor reduction efficacy at high doses (12 microg/g i.p.) was similar for melphalan and prophalan-L; however, fatal toxicity was associated with melphalan while prophalan-L exhibited significantly lower systemic toxicity. "
07/01/2007 - "The data corroborates the specificity of prophalan-L: activation by prolidase as well as prolidase-targeted cytotoxicity of prophalan-L: in cancer cell lines. "
07/01/2007 - "The bioactivation of prophalan-L: in the cancer cell lines exhibited high correlation with their prolidase expression levels (r (2) = 0.86). "
07/01/2007 - "The cytotoxicity of prophalan-L: (GI(50)) in cancer cells also showed high correlation with prolidase expression (r (2) = 0.88), while prophalan-D: was ineffective at comparable concentrations. "
11/01/2007 - "The tumor growth profiles in C57BL/6J mice injected with B16-F10 cells and treated with melphalan (5.5 microg/g i.p.) and equimolar concentrations of the prodrugs demonstrated significant difference between the control (buffered saline) and melphalan or prophalan-L but no significant difference between control and prophalan-D or between melphalan and prophalan-L. "
|3.||Weight Loss (Weight Reduction)
|3.||proline dipeptidase (prolidase)